Dr. Sonneveld on Incorporating Genomic Profiling Into Myeloma Management

Pieter Sonneveld, MD, PhD
Published: Wednesday, Oct 12, 2016



Pieter Sonneveld, MD, PhD, head of the Department of Hematology, Erasmus University Medical Center, discusses how the incorporation of genomic profiling will play into the overall management of patients with multiple myeloma.

Gene expression profiling should be introduced as a predictor in clinical trials to identify patients with high-risk disease, Sonnevald explains. This represents approximately 15% to 20% of patients with multiple myeloma.

If identified properly, these patients can be selected for different treatment modalities. This is becoming easier, he explains, with the various therapies now FDA approved in this setting.
SELECTED
LANGUAGE


Pieter Sonneveld, MD, PhD, head of the Department of Hematology, Erasmus University Medical Center, discusses how the incorporation of genomic profiling will play into the overall management of patients with multiple myeloma.

Gene expression profiling should be introduced as a predictor in clinical trials to identify patients with high-risk disease, Sonnevald explains. This represents approximately 15% to 20% of patients with multiple myeloma.

If identified properly, these patients can be selected for different treatment modalities. This is becoming easier, he explains, with the various therapies now FDA approved in this setting.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x